The iPhone giant may have approached the British supercar firm. Apple, though, has made few acquisitions, even to help it pioneer smartphones. While McLaren is high-tech, it's hard to see it taking Apple's car ambitions far. Fancy can run free when a company has $230 bln of cash.
The steel-making fuel is likely to give producers like BHP Billiton and Anglo American unexpected earnings boosts but there are few reasons to believe in a lasting rally. Weak Chinese metals demand and a potential revival in domestic supply could make gains fragile for investors.
Metals trader Sinosteel has agreed a $4 bln workout. The deal is a fudge, but spreads the pain more widely than expected. Meanwhile, a smaller miner has been allowed to fail. Both episodes suggest China is getting a bit tougher about debt problems in moribund sectors.
The U.S. central bank again declined to raise rates, leaving what hedgie Dan Loeb called the crack cocaine of loose monetary policy in place. The Fed counts talking to the market as one of its tools. But its story has changed so much that it might do better being less chatty.
The Bank of Japan has ditched its money-printing goals, pledging instead to keep 10-year interest rates at zero until inflation exceeds 2 pct. The central bank’s latest overhaul means it is less likely to run short of debt to buy, and eases the financial sector’s pain.
Postal Savings Bank is raising $7.4 bln after pricing shares in its IPO near the bottom of the range. The implied worth of the lender's equity is 0.93 times its forward book value, in line with peers. Higher costs and loan concentration means it is lucky to secure that.
Tim Cook may be revamping his approach to autonomous cars, while Elon Musk needs capital and corporate credibility. An Apple stake in Musk's electric carmaker would help both. Adding the Tesla founder to the iPhone giant's board could catalyze innovation there, too.
It's a logical move to name consumer head Emma Walmsley as the drugmaker's new chief executive. Pharma companies can learn a lot from the efficient personal care sector. Critics may see a doubling down on GSK’s HIV-to-Horlicks model, without a fix to its weaker pharma business.
A slowdown in venture capital is squeezing smaller tech hopefuls. Many have flocked to the "New Third Board" but it's hard to raise new equity on this moribund over-the-counter market. Some cash-strapped groups may sell out to larger rivals, or cut costs and hope for the best.
With two acquisitions worth over $30 bln pending – and the purchase of Alere, in particular, not going smoothly – the $62 bln health firm is vulnerable. Selling its eye-surgery unit to J&J gives Abbott needed financial breathing room and perhaps extra leverage with Alere.